The Tolerability of the Vaccine against P. aeruginosa in Children with Cystic Fibrosis and Congenital Lung Development

Chronic Pseudomonas aeruginosa infection is the most common cause of the failure in treatment and of adverse outcomes among children with congenital malformation of the lung (CML) and cystic fibrosis (CF). Purpose: To evaluatae the safety of anti Pseudomonas aeruginosa vaccine in children with congenital malformation of the lung and cystic fibrosis. Material and methods: 81 hospitalized children aged 5 to 17 with congenital malformation of the lung and cystic fibrosis participated in the research. 47 patients not experiencing exacerbation during basic therapy were vaccinated with anti Pseudomonas aeruginosa vaccine Pseudovac that consists of structural and extra-cellular antigens of the 8 immunotypes of Pseudomonas aeruginosa. The control group included 34 children who were not vaccinated, and had P. aeruginosa acquisition or infection. All the patients were under observation for the period of one year. Results: Pain in the injection site was registered in 74.5% and 76.6% of cases after the first and the second administration respectively. Further injections (3rd, 4th and 5th) of the vaccine caused much less local pain. In the majority of cases pain was mild and disappeared without medication within 24 hours. Redness in the injection site was registered in 29.8% of cases after the second administration of the vaccine. After further injections it was significantly less common. Local swelling in the injection site of not more than 25 mm after the first injection of the vaccine was registered in 57% of the cases, and in 100% of the cases after the second injection. It lasted less than 24 hours. Among vaccinated patients fever up to 37.5 degrees Celsius was registered in 23,4% of the cases. And up to 38.5 degrees in 4,3% of the cases. The reaction was observed within two hours after the injection and appeared regardless of the number of administrations lasting no longer than 24 hours. There appeared other single general reactions such as headache, dizziness or dry cough lasting up to 6 hours.

дети, муковисцидоз, хронические заболевания легких, синегнойная инфекция, вакцинация, безопасность, children, cystic fibrosis, chronic lung disease, pseudomonas infection, vaccination, safety

1. Høiby N, Frederiksen B. Hodson ME, Geddes D, editors. Microbiology In Cystic fibrosis. Arnold. 2000; 83 – 108.

2. Koch C. Early infection and progression of cystic fibrosis lung disease. Pediatric. Pulmonology. 2002; 34: 232 – 236.

3. Kosorok M.R., Zeng L., West S.E., Rock M.J., Splaingard M.L., Laxova A., et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol. 2001; 32: 277 – 87.

4. Lambiase A. Raia V., Pezzo M., Sepe A., Carnovale V., Rossano F. Microbiology of airway disease in a cohort of patients with cystic fibrosis. BMC Infect Dis. 2006; 6. (4): 12 – 18.

5. Kapranov N.I., Kashirskaya N.Y., Sherman V.D., Voronkova A.Yu., Shabalova L.A., Nikonova V.S. et al. Cystic fibrosis (Current Developments and Challenges). Guidelines. Moscow: Medical Genetics Research Center; 2011.

6. Kashirskaya N.Yu., Kapranov N.I. Place of inhaled forms of antibacterial drugs in the treatment of bacterial lung infection in cystic fibrosis patients. Pulmonology and Allergology. 2012; 3: 5 – 12.

7. Zakharov P.P., Rozinova N.N. Age evolution and outcomes of chronic inflammatory lung diseases in children. Difficult patient. 2008; 6 (9): 15 – 18)

8. Simonova O.I., Lazareva A.V., Morozova O.V., Ponomarenko O.A. Katosova L.K., Chistyakova V.P. et al. New possibilities of antibiotic therapy in acute and chronic respiratory diseases in children. Current Pediatrics. 2013; 12 (1). 123 – 130.

9. Semykin S.Yu., Postnikov S.S., Polikarpova S.V., Dubovik L.G., Saghatelyan M. Problems and prospects of antibiotic therapy for chronic Pseudomonas aeruginosa infections in patients with cystic fibrosis. VSP. 2010; 2: 94 – 98.

10. Semykin S.Yu. Experience with the drug Toby in patients with cystic fibrosis and infection caused by P. aeruginosa and B. cepacia, in the hospital. Medicine. 2009; 3; 75 – 80.

11. Li Z., Kosorok M.R., Farrell P.M., Laxova A., West S.E., Green C.G. et al. Longitudinal development of Mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. (Reprinted) JAMA, 2005; 293 (5): 581 – 588.

12. Canton R. Cobos N., de Gracia J., Baquero F., Honorato J., Gartner S. et al. Antimicrobial therapy for pulmonary pathogenic colonization and infection by Pseudomonas aeruginosa in cystic fibrosis patients Clin. Microbiol. Infect. 2005; 11: 690 – 703.

13. Wilson R., Dowling R.B. Pseudomonas aeruginosa and other related species. Thorax. 1998; 53: 213 – 219.

14. Kondratenko O.V., Lyamin A.V., Ivanov M.F., Konstantinov D.Yu, Peculiarities of Pseudomonas infections in patients with cystic fibrosis. Materials of scientificpractical conference Actual problems of infectious pathology. Tomsk. 2009: 77 – 79.

15. Gibson R.L., Burns J., Ramsey B. Pathophysiology & management of pulmonary infections in CF. Am. J. Respir. Crit. Care Med. 2003; 168: 918 – 951.

16. Kapranov N.I., Kashirskaya N.Yu., Nikonova V.S. Experience ambulatory inhaled antibiotic for patients with cystic fibrosis and Pseudomonas aeruginosa infections. Lechebnoe delo. 2010; 3: 35 – 40.

17. Cystic fibrosis foundation registry: annual data report. 2007: 12 – 13.

18. Kashirskaya N.Yu., Kapranov N.I. Place of inhaled forms of antibacterial drugs in the treatment of bacterial lung infection in cystic fibrosis patients. Pulmonology and Allergology. 2012; 3: 5 – 12.

19. Moroz A.F., Antsifirova, N.V., Baskakova N.G. Pseudomonas infection. Moscow: Medicine; 1988.

20. Sorde R. Pahissa A., Rello J. et al. Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis. Infection and drug resitence. 2011; 4: 31 – 41.

21. Simonova O.I., Gorinova Yu.V., Lazareva A.V., Katosova L.K., Burkina N.I., Chernevich V.P. Solving the problem of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis. 2014; 13 (1): 66 – 73.

22. Chebotar’ I.V. Mayansky AN, Кoncharovа E.N., Lazareva O.V., Chistyakova V.P. Antibiotic resistance biofilm bacteria. Clinical Microbiology and Antimicrobial Chemotherapy.. 2012; 14 (1): S. 51 – 58.

23. Radionovich A.M., Kashirskaya N.Yu., Kapranov N.I. Biofilms and its potential role in the pathogenesis of chronic bronchopulmonary process in cystic fibrosis patients infected with P. aerogenosa. Pulmonology (Cystic Fibrosis annex). 2006:109 – 112.

24. Fisher H. B., Devlin M. W., Gnabasik J. New Immunotype Schema for Pseudomonas aeruginosa Based on Protective Antigens. Journal of bacteriology. 1969; 98 (2): 835 – 836.

25. Medunitsyn N.V. Vaccinology. Moscow: Triada - X; 1999.

26. Kostinov M,P, ed. From preventive to therapeutic effect of vaccines against pneumococcal and Haemophilus influenzae type b infections in patients with bronchopulmonary pathology. Moscow: Human Health; 2007.

27. Plotkin S.A. Orenstein W.A., Offit P.A. Vaccines, 6-th ed. Elsevier: 2012.